Hims & Hers Health, Inc. (HIMS)
3 Reasons to Buy Hims & Hers Health Stock Now
Summer has officially begun, but some stocks are receiving a chilly reception today.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health Stock Soared This Week: Here's Why
Hims & Hers recently launched weight loss drugs at a disruptive price point. The company is growing revenue quickly.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Ultimate Growth Stock to Buy With $20 Right Now
Hims & Hers has entered the popular GLP-1 agonist category. Weight loss has quickly become a significant, potentially unexpected catalyst.
Hims & Hers Is Changing the Game
GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption.
Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy
Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy.
Weight loss drug roll-out sends Hims & Hers stock soaring
Weight loss drugs helped Hims & Hers Health (NYSE:HIMS) put value on, with the stock soaring some 30% higher in ‘afterhours' trade on Monday. The online consumer healthcare brand last night announced it will sell lower-priced GLP-1 weight loss injectables and oral weight loss medication in the United States, through a deal with its pharmacy supplier.
Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy
Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk's Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments.
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
Shares of Hims & Hers Health (NYSE: HIMS ) stock are skyrocketing higher by over 25% after the telehealth company announced that it would provide access to GLP-1 weight-loss injections. Hims & Hers has partnered with an undisclosed manufacturer of generic and 503B compounded injectable medications to provide the injections.
Hims & Hers Adds Weight-Loss Injections, Stock Soars
Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 29.4% to trade at $18.85 and earlier hitting a three-year high of $20.11.
